{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-107299","form_type":"8-K","ticker":"MAZE","cik":"0001842295","company_name":"Maze Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.305764+00:00","generated_at":"2026-05-17T14:51:59.774098+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Maze Therapeutics reports Q2 2025 net loss of $33.7M, cash $264.5M","bullets":["Net loss of $33.7M in Q2 2025 vs net income of $139.1M in Q2 2024 (prior year had $165M license revenue).","Cash and cash equivalents $264.5M as of June 30, 2025 vs $196.8M at Dec 31, 2024; runway into H2 2027.","R&D expenses increased to $28.1M in Q2 2025 from $19.5M in Q2 2024 due to clinical trial costs.","MZE782 Phase 1 proof-of-mechanism data expected Q3 2025; MZE829 Phase 2 HORIZON data expected Q1 2026.","No license revenue recognized in Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-107299","json":"https://secwatch.observer/filing/0000950170-25-107299.json","markdown":"https://secwatch.observer/filing/0000950170-25-107299.md","text":"https://secwatch.observer/filing/0000950170-25-107299.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842295/000095017025107299/0000950170-25-107299-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842295/000095017025107299/maze-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:51:59.774098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}